Form 4: Vigil Neuroscience Executive Reprices Stock Options to Reflect Fair Market Value

Christopher Verni, General Counsel of Vigil Neuroscience, repriced stock option awards to align with the company's fair market value as of May 3, 2024.

Summary

• On May 3, 2024, Vigil Neuroscience's General Counsel, Christopher Verni, engaged in transactions involving stock option awards.
• The transactions involved the repricing of existing stock option awards to reflect the fair market value of the company's common stock on the effective date of May 3, 2024.
• The exercise price of one stock option award was adjusted to $3.03 per share.
• A total of 150,000 options were repriced with an exercise price of $7.06 being reduced to $3.03.
• Another 85,000 options were repriced with an exercise price of $11.87 being reduced to $3.03.
• The repriced stock option awards are subject to a retention period, during which the original exercise price would be reinstated if exercised.
• The retention period ends one year after the effective date, upon a sale event, termination of service without cause or for good reason, or due to death or disability.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation adjustment, indicating a proactive approach to employee retention. The sentiment is neutral to slightly positive as it suggests the company is taking steps to maintain alignment between management and shareholder interests.

Positives

• The repricing of stock options aligns executive compensation with the current fair market value of the company's stock.
• The retention period incentivizes continued service and commitment from the General Counsel.

Risks

• If the Reporting Person exercises the repriced options during the Retention Period, the original exercise price will be reinstated, potentially reducing the benefit of the repricing.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and retention period terms of the stock options.

Industry Context

Stock option repricing is a mechanism companies use to incentivize employees when the stock price has fallen below the original option exercise price. It's a way to keep employees motivated and aligned with the company's long-term success.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, especially in the biotechnology industry where stock prices can be volatile.
• Companies like BioMarin Pharmaceutical and Amgen have used similar strategies to retain key employees during periods of stock price decline.
• The terms of the retention period are fairly standard, designed to ensure continued service and commitment from the employee.

Stakeholder Impact

• Shareholders may view the repricing as a positive step to retain key personnel.
• Employees, particularly the General Counsel, benefit from the repriced options, potentially increasing motivation and commitment.

Key Dates